NanoString Regroups After Pfizer Walks Away From R&D Pact
On May 17, 2017, Astellas Pharma Inc. issued a press release announcing its joint decision with Pfizer Inc. to discontinue the planned ENDEAR trial which is the subject of a collaboration with NanoString Technologies, Inc. (the “Company”). On the same date, the Company received informal notice from Astellas Pharma and Medivation, Inc., now owned by Pfizer Inc., regarding the termination. The Company was informed that the decision resulted from a portfolio review by Astellas Pharma and Pfizer, and was unrelated to the work performed by the Company in the development program. The Company expects to receive formal notice of termination of its collaboration agreement (the “Agreement”) with Astellas and Medivation imminently.